However, semaglutide may not be suitable for those with medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, pancreatitis, or severe gastrointestinal diseases, and these patients should explore alternate treatments with their provider
Combining GLP-1 & GIP therapy with a personalized diet and exercise plan can improve blood pressure, diabetes markers, and cholesterol contributing to better long-term cardiovascular and metabolic health
The convergence of scientific innovation and increasing global demand underscores the significant opportunities for both established and emerging players in this dynamic market
Innovations in formulation (e.g., oral delivery), combination therapies, and global pricing strategies will be critical
Patients often find that they feel full with smaller portions and are less interested in mindless snacking
Semaglutide has been studied for years and is widely used, so its safety profile is well understood